Table 1.

Patient characteristics (percent) in all patients and in patients with pre-HCT MRD assessment.

			All patients		Pre-HCT MRD known
			N	Percent	N	Percent
Total			143	100%	105	100%
Age
1–9			76	53%	55	52%
10+			67	47%	50	48%
Sex
Female			59	41%	43	41%
Male			84	59%	62	59%
Immunophenotypes
B-Precursor			113	79%	89	85%
T-Cell			27	19%	15	14%
Mixed Lineage (MLL)			3	2%	1	1%
Extramedullary disease at diagnosis
No			119	83%	91	87%
Yes			24	17%	14	13%
Leukemia risk group/donor type
High risk CR1			49	34%	39	37%
High risk CR2			69	48%	46	44%
Intermediate risk CR2			25	17%	20	19%
Stem cell source/HLA matching
Matched sibling			78	55%	57	54%
Other related donor BM (1 PBSC)			4	3%	2	2%
Unrelated donor – BM (5 PBSC)			34	24%	27	26%
Unrelated donor - cord blood			27	19%	19	18%
Leukemia risk group/stem cell source
Risk group		Stem cell source
High risk CR1		sib	29	20%	22	21%
High risk CR1		non-cord non-sib	17	12%	14	13%
High risk CR1		cord	3	2%	3	3%
High risk CR2		sib	24	17%	15	14%
High risk CR2		non-cord non-sib	21	15%	15	14%
High risk CR2		cord	24	17%	16	15%
Intermediate risk CR2		sib	25	17%	20	19%
MRD status pre-transplant
Negative			75	52%	75	71%
Positive, <0.1%			13	9%	13	12%
Positive, 0.1%+			17	12%	17	16%
Not donea			38	27%	0	0%
Grade of acute GVHD
None			88	62%	63	60%
1			20	14%	14	13%
2			19	13%	16	15%
3			9	6%	7	7%
4			7	5%	5	5%
Chronic GVHD
No			107	75%	76	72%
Yes			36	25%	29	28%
aGVHD and cGVHD
aGVHD	cGVHD
None	No		73	51%	51	49%
None	Yes		15	10%	12	11%
Grade I–III	No		29	20%	21	20%
Grade I–III	Yes		19	13%	16	15%
Grade IV	No		5	3%	4	4%
Grade IV	Yes		2	1%	1	1%